ID   ARHL2_HUMAN             Reviewed;         363 AA.
AC   Q9NX46; Q53G94; Q6IAB8; Q9BY47;
DT   06-FEB-2007, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   22-JUL-2015, entry version 125.
DE   RecName: Full=Poly(ADP-ribose) glycohydrolase ARH3;
DE            EC=3.2.1.143;
DE   AltName: Full=ADP-ribosylhydrolase 3;
DE   AltName: Full=[Protein ADP-ribosylarginine] hydrolase-like protein 2;
DE   Flags: Precursor;
GN   Name=ADPRHL2; Synonyms=ARH3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=12070318; DOI=10.1110/ps.0200602;
RA   Glowacki G., Braren R., Firner K., Nissen M., Kuehl M., Reche P.,
RA   Bazan J.F., Cetkovic-Cvrlje M., Leiter E., Haag F., Koch-Nolte F.;
RT   "The family of toxin-related ecto-ADP-ribosyltransferases in humans
RT   and the mouse.";
RL   Protein Sci. 11:1657-1670(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver cancer;
RA   Li Y., Wu T., Xu S., Ren S., Chen Z., Han Z.;
RT   "A novel gene expressed in human liver cancer tissue.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-209.
RC   TISSUE=Thyroid;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Skin;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, TISSUE SPECIFICITY, SUBCELLULAR LOCATION, ENZYME REGULATION,
RP   COFACTOR, AND MUTAGENESIS OF 77-ASP--ASP-78; 238-GLU--GLU-239 AND
RP   261-GLU--GLU-262.
RX   PubMed=16278211; DOI=10.1074/jbc.M510290200;
RA   Oka S., Kato J., Moss J.;
RT   "Identification and characterization of a mammalian 39-kDa poly(ADP-
RT   ribose) glycohydrolase.";
RL   J. Biol. Chem. 281:705-713(2006).
RN   [9]
RP   SUBCELLULAR LOCATION.
RX   PubMed=17991898; DOI=10.1128/MCB.01766-07;
RA   Niere M., Kernstock S., Koch-Nolte F., Ziegler M.;
RT   "Functional localization of two poly(ADP-ribose)-degrading enzymes to
RT   the mitochondrial matrix.";
RL   Mol. Cell. Biol. 28:814-824(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [11]
RP   CATALYTIC ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=22433848; DOI=10.1074/jbc.M112.349183;
RA   Niere M., Mashimo M., Agledal L., Dolle C., Kasamatsu A., Kato J.,
RA   Moss J., Ziegler M.;
RT   "ADP-ribosylhydrolase 3 (ARH3), not poly(ADP-ribose) glycohydrolase
RT   (PARG) isoforms, is responsible for degradation of mitochondrial
RT   matrix-associated poly(ADP-ribose).";
RL   J. Biol. Chem. 287:16088-16102(2012).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [14]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 19-363, AND MUTAGENESIS OF
RP   GLU-41; ASP-77; SER-148; TYR-149; ASN-151; HIS-182; ASP-314 AND
RP   THR-317.
RX   PubMed=17015823; DOI=10.1073/pnas.0606762103;
RA   Mueller-Dieckmann C., Kernstock S., Lisurek M., von Kries J.P.,
RA   Haag F., Weiss M.S., Koch-Nolte F.;
RT   "The structure of human ADP-ribosylhydrolase 3 (ARH3) provides
RT   insights into the reversibility of protein ADP-ribosylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:15026-15031(2006).
RN   [15]
RP   X-RAY CRYSTALLOGRAPHY (1.82 ANGSTROMS) OF 19-363, SUBSTRATE-BINDING
RP   SITE, AND METAL-BINDING SITES.
RX   PubMed=21892188; DOI=10.1038/nature10404;
RA   Slade D., Dunstan M.S., Barkauskaite E., Weston R., Lafite P.,
RA   Dixon N., Ahel M., Leys D., Ahel I.;
RT   "The structure and catalytic mechanism of a poly(ADP-ribose)
RT   glycohydrolase.";
RL   Nature 477:616-620(2011).
CC   -!- FUNCTION: Poly(ADP-ribose) synthesized after DNA damage is only
CC       present transiently and is rapidly degraded by poly(ADP-ribose)
CC       glycohydrolase. Poly(ADP-ribose) metabolism may be required for
CC       maintenance of the normal function of neuronal cells. Generates
CC       ADP-ribose from poly-(ADP-ribose), but does not hydrolyze ADP-
CC       ribose-arginine, -cysteine, -diphthamide, or -asparagine bonds.
CC       Due to catalytic inactivity of PARG mitochondrial isoforms, ARH3
CC       is the only PAR hydrolyzing enzyme in mitochondria.
CC       {ECO:0000269|PubMed:16278211}.
CC   -!- CATALYTIC ACTIVITY: Hydrolyzes poly(ADP-D-ribose) at glycosidic
CC       (1''-2') linkage of ribose-ribose bond to produce free ADP-D-
CC       ribose. {ECO:0000269|PubMed:22433848}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:16278211};
CC       Note=Binds 2 magnesium ions per subunit.
CC       {ECO:0000269|PubMed:16278211};
CC   -!- ENZYME REGULATION: Activity is enhanced by magnesium.
CC       {ECO:0000269|PubMed:16278211}.
CC   -!- SUBUNIT: Monomer. {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Mitochondrion matrix. Nucleus.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. {ECO:0000269|PubMed:16278211}.
CC   -!- SIMILARITY: Belongs to the ADP-ribosylglycohydrolase family.
CC       {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAK14922.1; Type=Frameshift; Positions=Several; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ313333; CAC85940.1; -; Genomic_DNA.
DR   EMBL; AJ427295; CAD20316.1; -; mRNA.
DR   EMBL; AF212236; AAK14922.1; ALT_FRAME; mRNA.
DR   EMBL; AK000453; BAA91174.1; -; mRNA.
DR   EMBL; CR457237; CAG33518.1; -; mRNA.
DR   EMBL; AK223037; BAD96757.1; -; mRNA.
DR   EMBL; AL138787; CAC21453.1; -; Genomic_DNA.
DR   EMBL; BC014169; AAH14169.1; -; mRNA.
DR   CCDS; CCDS402.1; -.
DR   RefSeq; NP_060295.1; NM_017825.2.
DR   UniGene; Hs.18021; -.
DR   PDB; 2FOZ; X-ray; 1.60 A; A=19-363.
DR   PDB; 2FP0; X-ray; 2.05 A; A/B=19-363.
DR   PDB; 2G4K; X-ray; 1.82 A; A=18-363.
DR   PDBsum; 2FOZ; -.
DR   PDBsum; 2FP0; -.
DR   PDBsum; 2G4K; -.
DR   ProteinModelPortal; Q9NX46; -.
DR   SMR; Q9NX46; 19-363.
DR   BioGrid; 120276; 3.
DR   IntAct; Q9NX46; 3.
DR   MINT; MINT-1420706; -.
DR   STRING; 9606.ENSP00000362273; -.
DR   PhosphoSite; Q9NX46; -.
DR   BioMuta; ADPRHL2; -.
DR   DMDM; 74753038; -.
DR   MaxQB; Q9NX46; -.
DR   PaxDb; Q9NX46; -.
DR   PeptideAtlas; Q9NX46; -.
DR   PRIDE; Q9NX46; -.
DR   Ensembl; ENST00000373178; ENSP00000362273; ENSG00000116863.
DR   GeneID; 54936; -.
DR   KEGG; hsa:54936; -.
DR   UCSC; uc001bzt.3; human.
DR   CTD; 54936; -.
DR   GeneCards; GC01P036554; -.
DR   HGNC; HGNC:21304; ADPRHL2.
DR   HPA; HPA027104; -.
DR   HPA; HPA027141; -.
DR   MIM; 610624; gene.
DR   neXtProt; NX_Q9NX46; -.
DR   PharmGKB; PA134903576; -.
DR   eggNOG; COG1397; -.
DR   GeneTree; ENSGT00390000015369; -.
DR   HOGENOM; HOG000225333; -.
DR   HOVERGEN; HBG080863; -.
DR   InParanoid; Q9NX46; -.
DR   KO; K11687; -.
DR   OMA; KCRDVYE; -.
DR   OrthoDB; EOG7D2FFB; -.
DR   PhylomeDB; Q9NX46; -.
DR   TreeFam; TF324754; -.
DR   BRENDA; 3.2.1.143; 2681.
DR   EvolutionaryTrace; Q9NX46; -.
DR   GeneWiki; ADPRHL2; -.
DR   GenomeRNAi; 54936; -.
DR   NextBio; 58054; -.
DR   PRO; PR:Q9NX46; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; Q9NX46; -.
DR   CleanEx; HS_ADPRHL2; -.
DR   Genevisible; Q9NX46; HS.
DR   GO; GO:0005759; C:mitochondrial matrix; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0004649; F:poly(ADP-ribose) glycohydrolase activity; IEA:UniProtKB-EC.
DR   GO; GO:0071451; P:cellular response to superoxide; IEA:Ensembl.
DR   InterPro; IPR005502; Ribosyl_crysJ1.
DR   Pfam; PF03747; ADP_ribosyl_GH; 1.
DR   SUPFAM; SSF101478; SSF101478; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Cytoplasm; Hydrolase; Magnesium;
KW   Metal-binding; Mitochondrion; Nucleus; Polymorphism;
KW   Reference proteome; Transit peptide.
FT   TRANSIT       1     27       Mitochondrion. {ECO:0000255}.
FT   CHAIN        28    363       Poly(ADP-ribose) glycohydrolase ARH3.
FT                                /FTId=PRO_0000277613.
FT   COMPBIAS      2     10       Poly-Ala.
FT   METAL        41     41       Magnesium 2.
FT   METAL        76     76       Magnesium 1.
FT   METAL        77     77       Magnesium 1.
FT   METAL        78     78       Magnesium 1.
FT   METAL       314    314       Magnesium 2.
FT   METAL       316    316       Magnesium 1.
FT   METAL       316    316       Magnesium 2.
FT   METAL       317    317       Magnesium 2.
FT   BINDING     254    254       Substrate. {ECO:0000250}.
FT   VARIANT     209    209       E -> K (in dbSNP:rs2236387).
FT                                {ECO:0000269|Ref.5}.
FT                                /FTId=VAR_030579.
FT   MUTAGEN      41     41       E->A,Q: Significant loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN      77     78       DD->NN: Complete loss of activity.
FT                                {ECO:0000269|PubMed:16278211}.
FT   MUTAGEN      77     77       D->N: Complete loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     148    148       S->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     149    149       Y->A: Significant loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     151    151       N->A: Partial loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     182    182       H->Q: Complete loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     238    239       EE->QQ: Slight reduction in activity.
FT                                {ECO:0000269|PubMed:16278211}.
FT   MUTAGEN     261    262       EE->QQ: Slight reduction in activity.
FT                                {ECO:0000269|PubMed:16278211}.
FT   MUTAGEN     314    314       D->E: Complete loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     314    314       D->N: Significant loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     317    317       T->A: Complete loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   MUTAGEN     317    317       T->S: Partial loss of activity.
FT                                {ECO:0000269|PubMed:17015823}.
FT   CONFLICT    109    109       K -> E (in Ref. 4; CAG33518).
FT                                {ECO:0000305}.
FT   HELIX        19     37       {ECO:0000244|PDB:2FOZ}.
FT   HELIX        38     40       {ECO:0000244|PDB:2FOZ}.
FT   HELIX        48     56       {ECO:0000244|PDB:2FOZ}.
FT   HELIX        77     92       {ECO:0000244|PDB:2FOZ}.
FT   HELIX        97    110       {ECO:0000244|PDB:2FOZ}.
FT   TURN        112    115       {ECO:0000244|PDB:2FP0}.
FT   HELIX       118    127       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       137    141       {ECO:0000244|PDB:2FOZ}.
FT   TURN        142    146       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       152    155       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       158    163       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       167    179       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       185    201       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       208    222       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       226    234       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       241    254       {ECO:0000244|PDB:2FOZ}.
FT   STRAND      255    257       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       260    267       {ECO:0000244|PDB:2FOZ}.
FT   STRAND      270    272       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       273    275       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       277    286       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       300    310       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       315    330       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       332    334       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       337    341       {ECO:0000244|PDB:2FOZ}.
FT   HELIX       346    360       {ECO:0000244|PDB:2FOZ}.
SQ   SEQUENCE   363 AA;  38947 MW;  5FD99F59F27CD29F CRC64;
     MAAAAMAAAA GGGAGAARSL SRFRGCLAGA LLGDCVGSFY EAHDTVDLTS VLRHVQSLEP
     DPGTPGSERT EALYYTDDTA MARALVQSLL AKEAFDEVDM AHRFAQEYKK DPDRGYGAGV
     VTVFKKLLNP KCRDVFEPAR AQFNGKGSYG NGGAMRVAGI SLAYSSVQDV QKFARLSAQL
     THASSLGYNG AILQALAVHL ALQGESSSEH FLKQLLGHME DLEGDAQSVL DARELGMEER
     PYSSRLKKIG ELLDQASVTR EEVVSELGNG IAAFESVPTA IYCFLRCMEP DPEIPSAFNS
     LQRTLIYSIS LGGDTDTIAT MAGAIAGAYY GMDQVPESWQ QSCEGYEETD ILAQSLHRVF
     QKS
//
